Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C19H21N3OS
CAS Number:
Molecular Weight:
339.45
MDL number:
NACRES:
NA.24
UNSPSC Code:
41116107
grade
pharmaceutical analytical impurity (PAI)
agency
USP
API family
quetiapine
manufacturer/tradename
USP
application(s)
pharmaceutical small molecule
format
neat
storage temp.
2-8°C
SMILES string
[s]1c2c(nc(c4c1cccc4)N3CCN(CC3)CCO)cccc2
InChI
1S/C19H21N3OS/c23-14-13-21-9-11-22(12-10-21)19-15-5-1-3-7-17(15)24-18-8-4-2-6-16(18)20-19/h1-8,23H,9-14H2
InChI key
OFLMIXVKBNAUIB-UHFFFAOYSA-N
General description
Find answers to frequently asked questions on USP products in USP FAQs.
QUETIAPINE DESETHOXY is a USP Pharmaceutical Analytical Impurity (PAI).
USP PAI are a product line of impurities suitable for research and analytical purposes, which help to ensure the quality and safety of medicines.
Associated Drug Substance: Quetiapine fumarate
Therapeutic Area: Psychiatrics
USP PAI are a product line of impurities suitable for research and analytical purposes, which help to ensure the quality and safety of medicines.
Associated Drug Substance: Quetiapine fumarate
Therapeutic Area: Psychiatrics
Application
QUETIAPINE DESETHOXY (USP PAI) is intended for use in analytical testing to detect, identify, and measure pharmaceutical impurities.
Features and Benefits
USP PAI advance your early analytical R&D and process development. PAI can be used in the following applications:
1. Conduct analytical tests during early formulation feasibility studies.
2. Determine degradation impurities produced during stress studies.
3. Develop, validate, and transfer analytical methods.
4. Perform spiking studies during process R&D to demonstrate depletion upon recrystallization.
5. Record retention times and/or spectra
6. Determine relative response factors.
7. Identify unknown impurities that formed during ICH stability conditions.
8. Identify impurities that are present in the Reference Listed Drug
9. Test for and profile impurities not listed in drug substance and drug product monographs.
1. Conduct analytical tests during early formulation feasibility studies.
2. Determine degradation impurities produced during stress studies.
3. Develop, validate, and transfer analytical methods.
4. Perform spiking studies during process R&D to demonstrate depletion upon recrystallization.
5. Record retention times and/or spectra
6. Determine relative response factors.
7. Identify unknown impurities that formed during ICH stability conditions.
8. Identify impurities that are present in the Reference Listed Drug
9. Test for and profile impurities not listed in drug substance and drug product monographs.
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Repr. 2 - STOT SE 3
target_organs
Central nervous system
Storage Class
10 - Combustible liquids
wgk
WGK 1
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.